The combination of psoralens and ultraviolet light (UVA,, also referred to as PUVA, is a potent modulator of epidermal cell growth and differentiation. Although it has been postulated that PUVA exerts its actions by binding to DNA, our laboratory has obtained evidence that a specific, saturable, high-affinity receptor site independent of the DNA mediates the biologic actions of these drugs. This receptor is a 22,000 molecular weight protein present in membrane and cytoplasmic fractions of responsive cell types. Treatment of cells with psoralens followed by UV light causes activation of the receptor. This leads to specific cell surface membrane alterations, in particular, phosphorylation of the receptor for epidermal growth factor (EGF). The EGF receptor is a transmembrane glycoprotein possessing intrinsic tyrosine kinase activity. Modification of the EGF receptor leads to a loss in its ability to bind EGF, as well as an inhibition of its tyrosine kinase activity. These data indicate that the psoralens act at the level of the cell membrane and that their biologic effects in the skin may be mediated by the ability of these drugs to disrupt normal growth factor functions.
INTRODUCTION
HE PSORALENS ARE PLANT-DERIVED CHEMICALS that are potent skin photosensitizers. Psora-T len analogs such as 8-methoxypsoralen and 4,5',8-trimethylpsoralen are used clinically in the treatment of a number of skin diseases including psoriasis and viti1igo.r') Following treatment with psoralens, patients are exposed to ultraviolet light in the range of 320-400 nm. Multiple treatments with this drug regimen, a procedure referred to as PUVA photochemotherapy, simultaneously leads to clearing of psoriatic plaques and skin pigmentation.(z) The therapeutic effects of PUVA are attributed to inhibition of keratinocyte proliferation and to stimulation of melanocyte growth and melanogenesis. During treatments for vitiligo, PUVA induces proliferation of pigment cells in hair bulbs and stimulates their migration into areas of unpigmented skin.(z)
Recently, our laboratory has proposed a model to explain the divergent effects of psoralens on the different cell types in the kin.'^.^) This is based on our discovery of specific actions of the psoralens that are not directly linked to DNA binding. We found that many cell types, including those derived from the skin, possess cell surface and cytoplasmic receptors for the p~oralens. 
LASKIN
Psoralen binding to these receptors is specific, saturable, and reversible. In human epithelial carcinoma cells, Scatchard binding analysis has revealed at least two classes of psoralen receptors with high (Kd = 19 nM, 1.8 X lo5 receptors per cell) and low (Kd = 4 pM, 7.1 X lo6 receptors per cell) affinity.(3) Several structurally related psoralen analogs including psoralen, 4,5',8-trimethylpsoralen, and 8-methoxypsoralen (8-MOP) also bind to these receptors. However, other types of drugs that have been used in the treatment of psoriasis such as methotrexate, retinoic acid, benzoyl peroxide, anthralin, and dexamethasone do not compete with the psoralens for receptor binding, demonstrating that psoralen receptor binding is highly specific.
The DNA is known to be a target for the psoralens. However, several lines of evidence from our laboratory suggest that the psoralen receptor is independent of the DNA.(3J In initial experiments utilizing fluorescence microscopy, we found that psoralens were localized in the cytoplasm and membranes of cells, but not in the nucleus. Cellular fractionation studies using radiolabeled 8-MOP bound to its receptor confirmed the subcellular localization of the receptor. Furthermore, in contrast to psoralen binding to its receptor, psoralen binding to DNA could not be saturated.(3) Taken together, these data indicate that the psoralen receptor is not associated with the DNA. This is supported by our identification of the psoralen receptor as a 22,000 molecular weight band in gels following sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis, and by our findings that the receptor was sensitive to protease, but not to nuclease treatment. (5) A model to explain the action of the psoralens based on the presence of specific receptors in responsive cell types is outlined in Figure 1 . According to this model, the biologic actions of the psoralens are mediated by their binding to receptors. Thus, following administration of 8-MOP or 4,5',8-trimethylpsoralen to patients, the psoralen binds with high affinity to receptor proteins either in the cell membrane or cytoplasm, forming a complex. Photoactivation of the complex by ultraviolet light initiates a biologic response, the nature of which depends on the cell type. In psoriatic keratinocytes, activation of the psoralen receptor leads to suppression of proliferation, while in melanocytes, cell growth and melanogenesis are stimulated.
Although the precise mechanisms by which psoralen receptor activation leads to alterations in epidermal cell growth are not known, recent evidence from our laboratory suggests that there is a specific membrane target. We found that photoactivated psoralens are potent inhibitors of binding of EGF to ~ells.(~,6) E G F is a small molecular weight protein known to be important in growth regulation. (7) Inhibition of EGF binding to cells by psoralens is rapid, and occurs through an indirect mechanism. (5, 6) In PAM 212 mouse epidermal cells, we identified at least two populations of EGF receptors with varying affinity for EGF. Psoralens, in combination with ultraviolet light, were found specifically to inhibit EGF binding to higher-affinity EGF receptors. (6) The EGF receptor is a 170,000 molecular weight transmembrane glycoprotein possessing intrinsic tyrosine kinase activityc7) EGF binding stimulates the tyrosine kinase activity of the receptor in the membrane. (7) Tyrosine phosphorylation is thought to be an important step in EGF-induced signal transduction leading to changes in the rates of cellular proliferation. Agents 
PSORALENS IN SKIN
that inhibit EGF receptor binding, such as the phorbol ester tumor promoters, are known to induce phosphorylation of the EGF receptor and inhibit its tyrosine kinase activity.@-lO) Using A431 human epidermoid cells, a cell line that overexpresses EGF receptors, we found that the psoralens, in combination with ultraviolent light, induce phosphorylation of the EGF receptor.(ll) While phorbol esters stimulate phosphorylation of the EGF receptor on serine and threonine residue, PUVA-induced phosphorylation appears to be specific for serine residues.@-lO) Our findings that PUVA inhibits EGF binding by an indirect mechanism and stimulates EGF receptor phosphorylation suggest that the photoactivated psoralen receptor stimulates a heterologous protein kinase in the cells, and that the EGF receptor is a substrate for this kinase. This would occur if the activated psoralen receptor is, by itself, a serine protein kinase. However, further experiments characterizing the purified psoralen receptor are required to verify this hypothesis.
Interfering with the tyrosine kinase activity of the EGF receptor significantly alters the ability of EGF to initiate growth regulatory signals in epidermal cells. We also found that the psoralens are potent inhibitors of EGF-stimulated EGF receptor tyrosine kinase activity in A43 1 epidermoid cells.(") This effect was dependent on ultraviolet light and was not observed in membrane fractions of A431 cells, which suggests that intact cells were required for the inhibition.
Based on the ability of PUVA to interfere with EGF receptor function, we propose a model for psoralen action in the skin (Fig. 2) . In epidermal cells, EGF binds to cell surface receptors forming a ligand-receptor complex. This complex is required for EGF to induce intracellular growth regulatory signals. The psoralens, following receptor binding and photoactivation, modify the EGF receptor by inducing receptor phosphorylation. This alters EGF receptor-ligand binding affinity as well as EGF receptor tyrosine kinase activity. This process alters the response of target cells to EGF. As described above, the specific response depends on the cell type. In some cell types growth is inhibited, while in others it is stimulated. Current studies in our laboratory are focused on analyzing the effect of the psoralens on other growth factors and their receptors.
SUMMARY
In the skin, PUVA treatment simultaneously stimulates melanocyte proliferation and suppresses keratinocyte growth. How PUVA treatment can have such divergent effects on different epidermal cell populations in the same tissue and at the same time may be explained by the existence of specific receptors that mediate the action of the psoralens. The response of the FIG. 2. A model for the mechanism of action of the psoralens in the skin. 1. Under normal conditions, EGF binds to its receptor (EGF R) forming a complex in responsive cell types in the skin. This process activates the receptor, leading to the production of intracellular growth regulatory signals. 2. PUVA, by activating the psoralen receptor, induces phosphorylation of the EGF receptor (*EGF R). 3. The modified EGF receptor has lower affinity for EGF and the complex has reduced tyrosine kinase activity. Thus, PUVA interferes with the ability of EGF to induce growth regulatory signals.
LASKIN different cell types to PUVA depends on the biologic activity induced by psoralen receptor activation. One potential site of action for PUVA in target cells is the EGF receptor, which provides direct evidence that the psoralens act at the level of the cell surface membrane. Further studies characterizing the biologic consequences resulting from PUVA altering the biologic functions of growth factors and their receptors is required for us to understand the mechanism of action of the psoralens.
